{"disease":{"id":"recurrent-bladder-cancer","name":"recurrent bladder cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07494864","title":"Effects of Microbiological and Immunological Factors on the Lower Urinary Tract","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"University of Zurich","has_results":false},{"nct_id":"NCT03933826","title":"CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":570,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT03174912","title":"In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both?","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Ankara Training and Research Hospital","has_results":false},{"nct_id":"NCT04907643","title":"Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes","phase":"NA","overall_status":"RECRUITING","enrollment_count":360,"lead_sponsor_name":"Cedars-Sinai Medical Center","has_results":false},{"nct_id":"NCT06733363","title":"A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":344,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT07000084","title":"Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":330,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT06770582","title":"Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03154190","title":"Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"Stanford University","has_results":true},{"nct_id":"NCT03237780","title":"Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":72,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05564403","title":"Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":66,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02495896","title":"Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":61,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT01828736","title":"Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie","has_results":false},{"nct_id":"NCT00118040","title":"Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04941287","title":"Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":57,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03257761","title":"Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":55,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT03602079","title":"Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Klus Pharma Inc.","has_results":false},{"nct_id":"NCT03513952","title":"Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04496219","title":"Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT01638533","title":"Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00749892","title":"Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02437370","title":"Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"University of California, Davis","has_results":false},{"nct_id":"NCT02122172","title":"Afatinib in Advanced Refractory Urothelial Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":32,"lead_sponsor_name":"University of Chicago","has_results":true},{"nct_id":"NCT04963153","title":"Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":24,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04267575","title":"Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites","phase":"NA","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Jerome Canady, M.D.","has_results":true},{"nct_id":"NCT01382706","title":"Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":15,"lead_sponsor_name":"University of Southern California","has_results":true},{"nct_id":"NCT03229278","title":"Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":true},{"nct_id":"NCT05559177","title":"An Open, Dose-escalation Clinical Study of Chimeric Exosomal Tumor Vaccines for Recurrent or Metastatic Bladder Cancer","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":9,"lead_sponsor_name":"Shanghai Pudong Hospital","has_results":false},{"nct_id":"NCT02808143","title":"Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Northwestern University","has_results":true},{"nct_id":"NCT04953104","title":"ARID1A and/or KDM6A Mutation and CXCL13 Expression","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02767921","title":"sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT03552796","title":"sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT03801278","title":"An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Five Prime Therapeutics, Inc.","has_results":false}],"total":32},"guidelines":[],"source":"Drug Landscape verified database"}